Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer

NCT03147963 ·Status: UNKNOWN ·Phase: PHASE2

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

NCT06088056 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

NCT06548178 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A ReaL World Study of DS-8201

NCT06945224 ·Status: ACTIVE_NOT_RECRUITING

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

NCT01301729 ·Status: COMPLETED ·Phase: PHASE4

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

NCT06833268 ·Status: COMPLETED

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

NCT06733233 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

NCT07152782 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

NCT06843681 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945 ·Status: RECRUITING ·Phase: PHASE3

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344793 ·Status: COMPLETED

Trastuzumab Deruxtecan in Advanced Breast Cancer

NCT07180264 ·Status: RECRUITING

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT07047755 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

NCT07057427 ·Status: RECRUITING ·Phase: PHASE3

Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy

NCT06161922 ·Status: RECRUITING

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

NCT04547907 ·Status: RECRUITING ·Phase: PHASE3

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

NCT05633914 ·Status: RECRUITING ·Phase: PHASE2

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

NCT06722599 ·Status: RECRUITING

Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen

NCT05731258 ·Status: RECRUITING

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

NCT07281001 ·Status: RECRUITING ·Phase: NA

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

NCT04158856 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT02896855 ·Status: COMPLETED ·Phase: PHASE3